

Please type a plus sign (+) inside this box C



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete If Known</b>	
				Application No.	10/733,698
				Filing Date:	December 11, 2003
				First Named Inventor	Tryggvason
				Group Art Unit	
				Examiner Name	unassigned
Sheet	1	of	3	Attorney Docket No.	94,778-H-CO

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
Ag	1	5,152,980		Strom et al.	10-06-1992	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	8/11/05
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Please type a plus sign (+) inside this box C



PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application No.	10/733,698
				Filing Date:	December 11, 2003
				First Named Inventor	Tryggvason
				Group Art Unit	
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket No.	94,778-H-CO

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
ASD		PIKKARAINEN ET AL., <i>Eur. J. Biochem</i> , 209:571-582 (1991).	
		PIKKARAINEN ET AL., <i>J. Biol. Chem.</i> , 263:6751-6758 (1988).	
		PIKKARAINEN ET AL., <i>J. Biol. Chem.</i> , 262:10454-10462 (1987).	
		VUOLTEENAHU ET AL., <i>J. Cell. Biol.</i> , 124:381-394 (1994).	
		HUDSON ET AL., <i>J. Biol. Chem.</i> , 268:26033-26036 (1993).	
		TRYGGVASON, <i>Current Opinion in Cell Biol</i> , 5:877-882 (1993).	
		KALLUNKI ET AL., <i>J. Biol. Chem.</i> , 119:679-693 (1992).	
		PYKE ET AL., <i>Am. J. Pathol.</i> , 145:1-10 (1994).	
		BURGESON ET AL., <i>Matrix Biology</i> , 14:209-211 (1994).	
		PULKKINEN ET AL., <i>Nature Genetics</i> , 6(3):293-297 (Mar. 1994).	
		ABERDAM ET AL., <i>Nature Genetics</i> , 6:299-304 (1994).	

Examiner Signature		Date Considered	7/26/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application No.	10/733,698		
		Filing Date:	December 11, 2003		
		First Named Inventor	Tryggvason		
		Group Art Unit			
		Examiner Name	Unassigned		
Sheet	3	of	3	Attorney Docket No.	94,778-H-CO

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
ASD		Embase Abstract No.: 97163048 (1997).	
		SNYDER ET AL., "λgt 11: Gene Isolation with Antibody Probes and Other Applications," <i>Methods in Enzymology</i> , 154:107-128 (1987).	
		HAO ET AL., "Differential Expression of Laminin 5 (α3β3γ2) by Human Malignant and Normal Prostate," <i>Am. J. Pathol.</i> , 149(4):1341-1349 (1996).	
		MATSUI ET AL., "γ <sup>2</sup> Chain of Laminin-5 is Recognized by Monoclonal Antibody GB3," <i>J. Invest. Dermatol.</i> , 105(5):648-652 (1995).	
		PYKE ET AL., "The γ <sup>2</sup> Chain of Kalinin/Laminin 5 is Preferentially Expressed in Invading Malignant Cells in Human Cancers," <i>Am. J. Pathol.</i> , 145(4):782-791 (Oct. 6, 1994).	
		PYKE ET AL., "Laminin-5 is a Marker of Invading Cancer Cells in Some Human Carcinomas...", <i>Cancer Res.</i> , 55:4132-4139 (1995).	
		VERRANDO ET AL., "Nicein (BM600) in Junctional Epidermolysis Bullosa: Polyclonal Antibodies Provide New Clues for Pathogenic Role," <i>J. Invest. Dermatol.</i> , 101(5):738-743 (1993).	
		VERRANDO ET AL., "Monoclonal Antibody GB3 Defines a Widespread Defect of Several Basement Membranes...", <i>Lab. Invest.</i> , 64(1):85-92 (1991).	
		WEWER ET AL., "Selective Assembly of Laminin Variants by Human Carcinoma Cells," <i>Lab. Invest.</i> , 71(5):719-730 (Nov. 1994).	
		MARINKOVICH ET AL., <i>J. Biol. Chem.</i> , 267(25):17900-17906 (2000).	

Examiner Signature		Date Considered	7/26/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231